Autoantibodies in scleroderma and their association with the clinical profile of the disease. A study of 66 patients from southern Brazil;Autoanticorpos em esclerodermia e sua associação ao perfil clínico da doença. Estudo em 66 pacientes do sul do Brasil

Anais Brasileiros de Dermatologia

Volumn 86, Issue 6, 2011, Pages 1075-1081

  Skare, Thelma Larocca ^a   Fonseca, Adriano Erlon ^b   Luciano, Alan Campos ^b   Azevedo, Pedro Ming ^a  

^a HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

^b Faculdade Evangelica do Parana FEPAR   (Brazil)

Author keywords

Antibodies; Antinuclear; Diffuse; Limited; Scleroderma

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; SCL 70 ANTIBODY; U1 RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; BRAZIL; CALCINOSIS; CARDIOMYOPATHY; ESOPHAGUS DISEASE; FEMALE; HUMAN; JOINT CONTRACTURE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MICROSTOMIA; MYOCARDITIS; MYOSITIS; PERICARDIAL DISEASE; PERICARDITIS; PERIPHERAL NEUROPATHY; PLEURISY; PREVALENCE; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SCAR; SCLERODERMA; TELANGIECTASIA; TENDON CONTRACTURE;

EID: 84856601756     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/s0365-05962011000600003     Document Type: Article

References (19)

1. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5:80-93.
2. Solomon DH, Kavanaugh AJ, Schur PH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47:434-44.
3. Reimer G, Steen VD, Penning CA, Medsger TA Jr, Tan EM. Cor relates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum. 1988;31:525-32.
4. Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger TA Jr. Differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum. 1994;37: 902-6.
5. Mayes MD. Systemic sclerosis. Clinical Aspects. In: Klippel JH, Stone JH, Crofford LJ, White PH, editors. Primer on Rheumatic Diseases. NewYork: Springer Sci & Business Media; 2008. p.343-50.
6. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of Systemic Lupus Er ythematosus. Arthritis Rheum. 1982,25:1272-7.
7. Akenson A, Fiori G, Krieg T, van den Hoogen FHJ, Seibold JR. The assessment of the patient with systemic sclerosis. The assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol. 2003,21(3 Suppl 29):S5-8.
8. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol. 2007;19:580-91.
9. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical and serological features and sur vival in 1012 Italian patients. Medicine (Baltimore). 2002;81:139-53.
10. Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol. 2008;158:487-95.
11. Reveille JD, Solomon DH; American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003,49:399-412.
12. Mc Neilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear anti-body patter ns and clinical manifestations of scleroderma. Arthritis Rheum. 1989,32:54-60.
13. Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical sociodemographic, serologic and immunogenetic determinants. Sem Arthritis Rheum. 2001;30:332-46.
14. Genth E, Mierau R, Genetzky P, von Mühlen CA, Kaufmann S, von Wilmowsky H, et al. Immunogenetic association of scleroder ma related antinuclear antibodies. Arthritis Rheum. 1990;33:657-65.
15. Lunderg I, Hedfors E. Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients. J Rheumatol. 1991;18:1511-9.
16. Perera A, Fertig N, Lucas M, Rodrigues-Reyna TSHUP, Steen VD, et al. Clinical subsets, skin thickness progression rate and serum antibody levels in systemic sclerosis patients with anti topoisomerase I antibody. Arthritis Rheum. 2007;56:2740-6.
17. Czirják L, Kumánovics G, Varjú C, Nagy Z, Pákosdi A, Szekanecz Z, et al. Survival and causes of death in 366 hungarian patients with systemic sclerosis. Ann Rheum Dis. 2008;67:59-63.
18. Allanore Y, Meune C, Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol. 2008;20: 697-702.
19. Wranicz J, Zielińska M, Cygankiewicz I, Dziankowska-Bar tkowiak B, Sysa-Jedrzejowska A. Early cardiovascular involvement in patients with systemic sclerosis (SSc). Med Sci Monit. 2002;8:CR78-82.